The latest biotech news

News and Trends 3 Mar 2023

Porton and DanausGT look to boost development of gene and cell therapy

Porton Advanced Solutions Ltd. and DanausGT Biotechnology Co., Ltd. have announced a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics. As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers solutions covering plasmids, cell therapy, gene therapy, oncolytic viruses, mRNA therapy, and bacterial therapy. DanausGT […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Mar 2023

Debiopharm adds to oncology pipeline

Debiopharm, an independent Swiss-based, biopharmaceutical company, has obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk. FT-3171 was developed by Forma Therapeutics, which was acquired by Novo Nordisk in 2022, and is currently in late preclinical development. FT-3171 (Debio 0432) could […]

March 3, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 3 Mar 2023

Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor

Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for immune checkpoint inhibitor LR 09. LR 09 is a novel metabolic immune checkpoint inhibitor, for the treatment of patients with hematological malignancies who are diagnosed with a relapse after allogeneic stem […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Antiverse identifies therapeutic antibodies targeting GPCRs

Antiverse Ltd has announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. Antiverse, which was featured as one of our five Welsh biotech startups making waves in 2023, also announced it has raised $3 million funding, which will enable in-house development of the […]

March 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Partnership formed to develop miRNA to treat pancreatic cancer

RNA delivery and therapeutics company SiSaf Ltd is to collaborate with the University of Leipzig in Germany to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer. The collaboration will combine SiSaf’s work in RNA delivery using its Bio-Courier silicon-stabilized hybrid lipid nanoparticles (sshLNPs) and the […]

March 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Genomic medicine company Chroma raises $135M

Chroma Medicine, Inc., a genomic medicine company advancing single-dose epigenetic editing therapeutics, has completed a $135 million Series B financing. The funding was led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, […]

March 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Ten new companies join BioInnovation Institute’s Venture Lab program

BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating life science research, has added 10 new companies to its Venture Lab acceleration program for early-stage companies. The cohort is aligned with BioInnovation Institute’s focus on supporting innovative early-stage start-ups within human and planetary health. The 12-month program is designed to support start-up companies with […]

March 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

New lipid nanoparticle CRISPR delivery system developed

Lipid nanoparticles have been used to encapsulate CRISPR-Cas9 and deliver it to cells in mice, where it was highly effective at knocking down expression of a target protein. Gene therapy is a potential mode of treatment for a wide variety of diseases caused by genetic mutations. While it has been an area of diverse and […]

March 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 28 Feb 2023

What’s happening on Rare Disease Day?

Rare Disease Day 2023 is on February 28. The day is dedicated to raising awareness for the approximately 300 million people around the world living with a rare disease. More than 6,000 rare diseases are characterized by a diversity of disorders and symptoms that vary not only from disease to disease, but also from patient […]

February 28, 2023 - 8 minutesmins - By Jim Cornall

News and Trends 28 Feb 2023

European Commission approves first gene therapy for hemophilia B

The European Commission has approved the first gene therapy for the treatment of hemophilia B developed by biotech company CSL Behring. The one-time gene therapy etranacogene dezaparvovec sold under the brand name Hemgenix is manufactured by UniQure Inc. and distributed by CSL Behring. The gene therapy is used to treat severe and moderately severe hemophilia […]

February 28, 2023 - 3 minutesmins - By Roohi Mariam Peter

News and Trends 28 Feb 2023

Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer

Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer. The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product […]

February 28, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 28 Feb 2023

GC Biopharma acquiring hemophilia rare disease pipeline

GC Biopharma Corp., a South Korean provider of biopharmaceutical products, has signed an asset purchase agreement with Catalyst Biosciences to acquire three programs related to the orphan hematology disorders. The agreement includes Marzeptacog alfa (MarzAA), an engineered factor VIIa, which is ready for phase 3 clinical stage development. In its previous clinical development trials, MarzAA […]

February 28, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Porton and DanausGT look to boost development of gene and cell therapy

Debiopharm adds to oncology pipeline

Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor

Antiverse identifies therapeutic antibodies targeting GPCRs

Partnership formed to develop miRNA to treat pancreatic cancer

Genomic medicine company Chroma raises $135M

Ten new companies join BioInnovation Institute’s Venture Lab program

New lipid nanoparticle CRISPR delivery system developed

What’s happening on Rare Disease Day?

European Commission approves first gene therapy for hemophilia B

Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer

GC Biopharma acquiring hemophilia rare disease pipeline

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!